|
GB201203051D0
(en)
*
|
2012-02-22 |
2012-04-04 |
Ucb Pharma Sa |
Biological products
|
|
KR101503341B1
(ko)
|
2014-03-12 |
2015-03-18 |
국립암센터 |
자가암항원 특이적 cd8+ t 세포의 분리 및 증식방법
|
|
TW201632559A
(zh)
|
2015-02-22 |
2016-09-16 |
索倫多醫療公司 |
結合ｃｄ１３７之抗體治療劑
|
|
JP2018520650A
(ja)
*
|
2015-05-21 |
2018-08-02 |
アリゲーター・バイオサイエンス・アーベー |
新規のポリペプチド
|
|
KR102379464B1
(ko)
|
2016-06-20 |
2022-03-29 |
키맵 리미티드 |
항-pd-l1 항체
|
|
KR20190022632A
(ko)
|
2016-06-20 |
2019-03-06 |
에프-스타 베타 리미티드 |
Lag-3 결합 구성원
|
|
SG11201811431VA
(en)
|
2016-07-14 |
2019-01-30 |
Genmab As |
Multispecific antibodies against cd40 and cd137
|
|
GB201612520D0
(en)
|
2016-07-19 |
2016-08-31 |
F-Star Beta Ltd |
Binding molecules
|
|
GB201619648D0
(en)
*
|
2016-11-21 |
2017-01-04 |
Alligator Bioscience Ab |
Novel antibodies and uses thereof
|
|
WO2018098370A1
(en)
|
2016-11-23 |
2018-05-31 |
Immunoah Therapeutics, Inc. |
4-1bb binding proteins and uses thereof
|
|
US10174122B2
(en)
*
|
2017-01-06 |
2019-01-08 |
Eutilex Co., Ltd. |
Anti-human 4-1BB antibodies and uses thereof
|
|
US20180325931A1
(en)
|
2017-01-21 |
2018-11-15 |
Ningbo Zhiming Biotechnology Co., Ltd. |
Use of paeoniflorin-6'-o-benzenesulfonate in treatment of sjögren's syndrome
|
|
IL268836B2
(en)
|
2017-02-24 |
2024-04-01 |
Macrogenics Inc |
Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereof
|
|
JP7297672B2
(ja)
*
|
2017-04-13 |
2023-06-26 |
アジェナス インコーポレイテッド |
抗ｃｄ１３７抗体およびその使用方法
|
|
SG11201913137VA
(en)
|
2017-07-11 |
2020-01-30 |
Compass Therapeutics Llc |
Agonist antibodies that bind human cd137 and uses thereof
|
|
US11512134B2
(en)
|
2017-08-01 |
2022-11-29 |
Eli Lilly And Company |
Anti-CD137 antibodies
|
|
CA3071383C
(en)
*
|
2017-08-01 |
2022-04-12 |
Eli Lilly And Company |
Anti-cd137 antibodies
|
|
SG11202000198QA
(en)
|
2017-08-04 |
2020-02-27 |
Genmab As |
Binding agents binding to pd-l1 and cd137 and use thereof
|
|
CN111511762B
(zh)
|
2017-08-21 |
2025-05-06 |
天演药业公司 |
抗cd137分子及其用途
|
|
CN111194323B
(zh)
*
|
2017-10-10 |
2024-07-09 |
努玛治疗有限公司 |
多特异性抗体
|
|
WO2019089753A2
(en)
|
2017-10-31 |
2019-05-09 |
Compass Therapeutics Llc |
Cd137 antibodies and pd-1 antagonists and uses thereof
|
|
TWI701259B
(zh)
|
2017-11-09 |
2020-08-11 |
大陸商上海懷越生物科技有限公司 |
４﹘１ｂｂ抗體及其製備方法和應用
|
|
US11851497B2
(en)
|
2017-11-20 |
2023-12-26 |
Compass Therapeutics Llc |
CD137 antibodies and tumor antigen-targeting antibodies and uses thereof
|
|
WO2019104716A1
(en)
*
|
2017-12-01 |
2019-06-06 |
Adagene Inc. |
Methods for using cd137 ligand as biomarker for treatment with anti-cd137 antibody
|
|
WO2019121906A1
(en)
|
2017-12-19 |
2019-06-27 |
F-Star Beta Limited |
Specific pd-l1 binding sequences inserted in a ch3 domain
|
|
WO2019148445A1
(en)
|
2018-02-02 |
2019-08-08 |
Adagene Inc. |
Precision/context-dependent activatable antibodies, and methods of making and using the same
|
|
JP2021514953A
(ja)
*
|
2018-02-23 |
2021-06-17 |
バイスクルテクス・リミテッド |
多量体二環式ペプチドリガンド
|
|
CA3094763C
(en)
|
2018-03-23 |
2024-01-02 |
Eli Lilly And Company |
Anti-cd137 antibodies for combination with anti-pd-l1 antibodies
|
|
AU2018418224B2
(en)
*
|
2018-04-09 |
2025-04-17 |
Oricell Therapeutics Co., Ltd. |
Anti-PD-L1 antibody and use thereof
|
|
CA3099308A1
(en)
|
2018-05-21 |
2019-11-28 |
Compass Therapeutics Llc |
Compositions and methods for enhancing the killing of target cells by nk cells
|
|
CN112384532B
(zh)
*
|
2018-06-29 |
2025-01-10 |
艾利妥 |
抗SIRP-β1抗体及其使用方法
|
|
GB201811450D0
(en)
|
2018-07-12 |
2018-08-29 |
F Star Delta Ltd |
Mesothelin and CD137 binding molecules
|
|
GB201811403D0
(en)
|
2018-07-12 |
2018-08-29 |
F Star Beta Ltd |
Antibody molecules
|
|
PL3820569T3
(pl)
|
2018-07-12 |
2025-07-14 |
Invox Pharma Limited |
Cząsteczki przeciwciał, które wiążą PD-L1 oraz CD137
|
|
GB201811404D0
(en)
*
|
2018-07-12 |
2018-08-29 |
F Star Beta Ltd |
Anti-CD137 Antibodies
|
|
BR112021000282A2
(pt)
|
2018-07-12 |
2021-04-06 |
F-Star Beta Limited |
Moléculas de anticorpo que se ligam a cd137 e ox40
|
|
GB201811408D0
(en)
|
2018-07-12 |
2018-08-29 |
F Star Beta Ltd |
CD137 Binding Molecules
|
|
GB201811410D0
(en)
|
2018-07-12 |
2018-08-29 |
F Star Beta Ltd |
OX40 Binding molecules
|
|
GB201811415D0
(en)
|
2018-07-12 |
2018-08-29 |
F Star Beta Ltd |
Anti-Mesothelin Anti bodies
|
|
EP3823988A1
(en)
|
2018-07-19 |
2021-05-26 |
Eli Lilly and Company |
Bispecific antibodies targeting immune checkpoints
|
|
AU2019312200B2
(en)
|
2018-07-23 |
2024-11-14 |
Heidelberg Pharma Research Gmbh |
Use of anti-CD137 antibody drug conjugate (ADC) in allogeneic cell therapy
|
|
WO2020023553A1
(en)
|
2018-07-24 |
2020-01-30 |
Inhibrx, Inc. |
Multispecific polypeptide constructs containing a constrained cd3 binding domain and a receptor binding region and methods of using the same
|
|
CA3110006A1
(en)
*
|
2018-09-12 |
2020-03-19 |
Eucure (Beijing) Biopharma Co., Ltd |
Anti-tnfrsf9 antibodies and uses thereof
|
|
US12331320B2
(en)
|
2018-10-10 |
2025-06-17 |
The Research Foundation For The State University Of New York |
Genome edited cancer cell vaccines
|
|
EP3864045A2
(en)
|
2018-10-11 |
2021-08-18 |
Inhibrx, Inc. |
Dll3 single domain antibodies and therapeutic compositions thereof
|
|
WO2020076992A1
(en)
|
2018-10-11 |
2020-04-16 |
Inhibrx, Inc. |
5t4 single domain antibodies and therapeutic compositions thereof
|
|
WO2020077257A1
(en)
|
2018-10-11 |
2020-04-16 |
Inhibrx, Inc. |
Pd-1 single domain antibodies and therapeutic compositions thereof
|
|
CN113286825B
(zh)
*
|
2018-11-30 |
2024-06-18 |
爱必乐生物公司 |
抗pd-l1/抗4-1bb双特异性抗体及其用途
|
|
JP7558534B2
(ja)
*
|
2019-01-02 |
2024-10-01 |
キューエルエスエフ バイオセラピューティック インコーポレイテッド |
Ｃｄ１３７アゴニスト性抗体とその使用
|
|
JP7695698B2
(ja)
*
|
2019-01-14 |
2025-06-19 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
細胞内部移行をモジュレートするための組成物および方法
|
|
SG11202109163YA
(en)
*
|
2019-02-26 |
2021-09-29 |
Sorrento Therapeutics Inc |
Antigen binding proteins that bind bcma
|
|
SG11202110287QA
(en)
|
2019-04-24 |
2021-10-28 |
Heidelberg Pharma Res Gmbh |
Amatoxin antibody-drug conjugates and uses thereof
|
|
WO2020247290A1
(en)
*
|
2019-06-04 |
2020-12-10 |
Academia Sinica |
Ligands targed to epidermal growth factor receptors and compositions for use in treating tumors
|
|
CA3285695A1
(en)
|
2019-06-26 |
2026-03-02 |
Ap Biosciences, Inc. |
Antibodies for t-cell activation
|
|
US11466086B2
(en)
|
2019-10-11 |
2022-10-11 |
Nanjing Leads Biolabs Co., Ltd. |
Antibodies binding 4-1BB and uses thereof
|
|
EP4100439A4
(en)
*
|
2020-02-05 |
2024-05-29 |
The Board Of Regents Of The University Of Texas System |
NOVEL LILRB2 ANTIBODIES AND USES THEREOF
|
|
WO2021209017A1
(zh)
*
|
2020-04-17 |
2021-10-21 |
苏州丁孚靶点生物技术有限公司 |
一种特异性结合cd137的制剂及其用途
|
|
KR20230012559A
(ko)
|
2020-05-19 |
2023-01-26 |
베링거 인겔하임 인터내셔날 게엠베하 |
암 치료를 위한 결합 분자
|
|
CN113842456B
(zh)
*
|
2020-06-28 |
2022-07-26 |
上海齐鲁制药研究中心有限公司 |
一种抗人4-1bb的单克隆抗体制剂及其用途
|
|
CN116194124A
(zh)
*
|
2020-07-31 |
2023-05-30 |
中外制药株式会社 |
包含表达嵌合受体的细胞的药物组合物
|
|
CN116199778B
(zh)
*
|
2021-12-01 |
2025-06-03 |
上海君实生物医药科技股份有限公司 |
抗4-1bb抗体及其用途
|
|
CN115975032B
(zh)
*
|
2022-12-19 |
2024-06-07 |
华润生物医药有限公司 |
一种cldn18.2抗体及其应用
|
|
AU2024330458A1
(en)
*
|
2023-09-01 |
2026-02-12 |
Amgen Inc. |
Molecules for treatment of cancer
|
|
WO2025189194A1
(en)
*
|
2024-03-08 |
2025-09-12 |
Dana-Farber Cancer Institute, Inc. |
Antibodies against vegf and methods of use thereof
|